Visken (pindolol) / Novartis 
Welcome,         Profile    Billing    Logout  
 17 Diseases   5 Trials   5 Trials   159 News 


«123
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Phase classification:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=134, Recruiting, 
    Phase classification: P=N/A --> P
  • ||||||||||  Visken (pindolol) / Novartis
    Preclinical, Journal:  NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. (Pubmed Central) -  Feb 10, 2018   
    Furthermore, we also observed NO-dependent alleviation of the TPA-induced NK cell depletion in the ear tissues by heptaminol pretreatment. Together our results suggest that stimulation of NO generation from constitutive synthases may be primarily responsible for the reported antihyperplastic and NK cell-preserving effects of the β-blockers, and that similar effects may be observed in other immunity normalizing compounds that also promote endothelial NO synthesis.
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Trial primary completion date:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Nov 28, 2017   
    P=N/A,  N=134, Recruiting, 
    Together our results suggest that stimulation of NO generation from constitutive synthases may be primarily responsible for the reported antihyperplastic and NK cell-preserving effects of the β-blockers, and that similar effects may be observed in other immunity normalizing compounds that also promote endothelial NO synthesis. Trial primary completion date: Jun 2018 --> Dec 2018
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Trial primary completion date:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Mar 8, 2017   
    P=N/A,  N=134, Recruiting, 
    Trial primary completion date: Jun 2018 --> Dec 2018 Trial primary completion date: Mar 2017 --> Jun 2018
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Trial primary completion date:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Sep 6, 2016   
    P=N/A,  N=134, Recruiting, 
    Trial primary completion date: Mar 2017 --> Jun 2018 Trial primary completion date: Aug 2016 --> Mar 2017
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Trial primary completion date:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Sep 24, 2015   
    P=N/A,  N=134, Recruiting, 
    Trial primary completion date: Aug 2016 --> Mar 2017 Trial primary completion date: Aug 2015 --> Aug 2016
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Enrollment change:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Jun 11, 2015   
    P=N/A,  N=134, Recruiting, 
    Trial primary completion date: Aug 2015 --> Aug 2016 N=50 --> 134
  • ||||||||||  Visken (pindolol) / Novartis
    Enrollment change, Trial termination, Trial primary completion date:  ESPION: EScitalopram PIndolol ONset of Action (clinicaltrials.gov) -  May 27, 2015   
    P2/3,  N=18, Terminated, 
    N=50 --> 134 N=135 --> 18 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Apr 2013; Recruitment difficulties